Atrinsic (NASDAQ:PTIX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.
Atrinsic Price Performance
Shares of NASDAQ PTIX opened at $3.22 on Friday. Atrinsic has a one year low of $2.25 and a one year high of $15.26. The stock has a market capitalization of $1.90 million, a PE ratio of -0.34 and a beta of 0.36. The business’s fifty day moving average price is $3.26 and its 200-day moving average price is $3.64.
Atrinsic (NASDAQ:PTIX – Get Free Report) last released its quarterly earnings data on Wednesday, September 10th. The company reported ($1.37) earnings per share (EPS) for the quarter.
About Atrinsic
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Further Reading
- Five stocks we like better than Atrinsic
- What is the S&P 500 and How It is Distinct from Other Indexes
- Tesla’s U.S. Market Is At An 8-Year Low… How Bad Could It Get?
- What is the Australian Securities Exchange (ASX)
- Congress: The Biggest Trades Impacting Markets Today
- How to Capture the Benefits of Dividend Increases
- 3 Companies Boosting Buybacks While Others Pull Back
Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.
